Imatinib, used in gastrointestinal stromal tumor (GIST) or chronic myeloid leukemia (CML), can also inhibit IDO expression, by inducing Treg apoptosis and activation of CD8+ T cells [150]. Here, CD8A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.